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ABSTRACT. Bw gain is controlled by energy intake 
on one hand and expenditure on the other. The com-
ponents of energy expenditure are basal metabo-
lism, exercise induced thermogenesis and adaptive 
UNCOUPLING PROTE/N-1 (UCP1) 
In rodents, brown adipose tissue (BAT) is an im-
portant site of adaptive thermogenesis. Cold ex-
posure has for long been known to induce, via stim-
ulation of the sympathetic nervous system, an in-
crease in BAT thermogenesis referred to as adap-
tive cold-induced thermogenesis (CIT), (1). Further-
more, it has been observed that voluntary overeat-
ing induced in rats by the administration of a palat-
able, so-called "cafeteria" diet also induced an in-
crease in BAT thermogenesis which was called 
adaptive diet-induced thermogenesis (OIT) (2). 
The main producer of heat in BAT is the uncoupling 
protein-1 (UCP1). This mitochondria inner mem-
brane protein uncouples oxidative phosphorylation 
by dissipating the proton gradient generated by 
the re-oxidation of NAOH H+ in the respiratory 
chain. The UCP1-mediated proton transport re-
quires the presence of fatty acids and is specifical-
Iy inhibited by purine di-and triphosphate nu-
cleotides (3). The consequence of UCP1 activity is 
a decrease in the amount of ATP formed by the 
ATP synthase and energy dissipation as heat. 
UCP1 knockout mice were generated and they 
were unable to maintain their body temperature 
upon cold exposure but did not become obese (4). 
These data confirmed the importance of UCP1 in 
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thermogenesis. In this short review we shall discuss 
the main determinants of adaptive thermogenesis. 
(J. Endocrinol. Invest. 25: 862-866,2002) 
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CIT and suggested that, in UCP1 knockout mice, 
alternative mechanisms for maintaining body mass 
wh ich could not protect against the cold were 
turned on, 
In humans, BAT is present in newborn babies and 
decreases in 4-6 months after birth (5, 6). It is there-
fore generally believed that there is no UCP1 in hu-
man adults. 
THE ßTADRENOCEPTOR - UCP1 AX/S 
The family of the ß-adrenoceptors were considered 
to consist of ß1- and ß-rsubtypes until1989 when 
a third subtype was cloned (7). This third subtype 
called the ß3-adrenoceptor was found to be the 
predominant ß-subtype in rodent BAT and white 
adipose tissue (WAT) (8, 9). When the BAT sympa-
thetic nervous system activity is increased by cold 
exposure or overfeeding, the stimulatory effect on 
UCP1 activity and expression is therefore mediat-
ed essentially by the ß3-adrenoceptor (9). There-
fore, the ß3-adrenoceptor-UCP1-axis is a major de-
terminant of rodent adaptive thermogenesis, 
The ß3-adrenoceptor was found to be down-regu-
lated in obese fa/fa Zucker rat BAT and WAT (8) 
and in obese ob/ob mouse adipose tissues com-
pa red to lean animals (10). 
In ß3-adrenoceptor knockout mice, the capacity to 
adapt to a cold environment was fully preserved, but 
there was an increase in fat deposition under basal 
conditions and in response to a high fat diet (11). 
These data confirmed the importance of the ß3-
adrenoceptor in OIT and suggested that, in the ß3-
adrenoceptor knockout mice, alternative mechanisms 
for maintaining body temperature were turned on. 
In rodents, cold exposure was found to recruit mul-
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tilocular cells expressing UCPl in WAT (12). The ef-
fect of cold was mimicked by administration of the 
ß3-adrenoceptor agonist CL316'249 (13-16). The 
precursors ofthe brown adipocyte-like cells in WAT 
could be brown preadipocytes expressing the ß3-
adrenoceptor or, as recently hypothesized, mature 
white adipocytes undergoing a transdifferentiation 
(17). We showed that the increase in UCPl expres-
sion in the WAT induced by cold-acclimation was to-
tally blunted in C57BL/6J ß3-adrenoceptor knockout 
mice. These results suggest that brown adipocyte-
like cell recruitment in the WAT is specifically con-
trolled by the ßTadrenoceptor (submitted). 
In humans, the ß3-adrenoceptor is expressed in 
newborn baby BAT, although at a relatively lower 
level in comparison to the ß1/ßrsubtypes than in 
rodent BAT (18) and the question of its existence 
or not in WAT is controversial. No, or only a very 
low expression of ß3-adrenoceptor mRNA could be 
detected in various human WAT depots (9). A role 
of the ß3-adrenoceptor in the control of lipolysis in 
WAT has also been difficult to prove. Among ß3-
agonists known to stimulate lipolysis in rodent fat 
cells, only the ß1/ßradrenoceptor antagonist and 
ß3-adrenoceptor agonist CGP 12177 was found to 
exert a lipolytic action in isolated human white 
adipocytes (19,20). These observations, which sup-
ported the existence of an active ß3-adrenoceptor 
in human WAT, should now be reevaluated since 
CGP 12177 has recently been shown to behave as 
an agonist of a modified form of the ß1-adreno-
ceptor (21). New derivatives have recently been re-
ported to displaya ß1/ßz-adrenoceptor antagonist-
insensitive lipolytic effect in isolated human white 
adipocytes. These results were interpreted as indi-
cating that there is a ß3-adrenoceptor-mediated 
lipolytic response in human white adipocytes (22). 
Human genetic studies are of great importance for 
the evaluation of the biological role of a gene of 
interest in vivo. In 1995, amissense mutation in 
codon 64 of the ß3-adrenoceptor gene (T rp64Arg) 
was described which seemed to be responsible for 
features of insulin resistance and for a tendency to 
gain weight (23-25). In arecent review analyzing 
more than 100 published articles, Shuldiner et al. 
(26) concluded, based mostlyon meta-analyses and 
functional studies, that the ß3-adrenoceptor has the 
perfect profile of an obesity-susceptibility gene. 
The ß3-adrenoceptor - UCPl axis is a target of lep-
tin. It has been shown that this adipocyte-derived 
hormone via stimulation ofthe sympathetic nervous 
system increases BAT UCPl expression and ther-
mogenesis (27-29). 
The ß3-adrenoceptor - UCPl axis would be a good 
target for anti-obesity drugs. If brown preadipo-
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cytes expressing the ß3-adrenoceptor are indeed 
present in human WAT, ß3-adrenoceptor agonists 
with a high affinity for these receptors might, by in-
ducing the recruitment of brown adipocyte-like cells 
in the WAT depots, favor body energy expenditure. 
UNCOUPLING PROTEIN-3 (UCP3) 
In 1997, two novel members of the mitochondrial 
carrier family were discovered (30, 31). Based on 
their amino acid sequence identities with UCP1, 
they were called UCP2 and UCP3. UCP2 was ex-
pressed in most tissues studied and UCP3 mainly 
in skeletal muscle. An interesting feature of these 
novel uncoupling proteins was their high level of 
expression in human tissue (30, 31). Therefore, 
UCP3 might be an important determinant in the 
regulation of energy expenditure in humans. We 
will focus on UCP3 in this section. 
UCP3 has been shown in heterologous yeast and 
mammalian cell expression systems to decrease mi-
tochondrial membrane potential, and to increase 
whole cell basal 02 consumption and mitochon-
dria State 4 respiration. This was considered a 
demonstration that UCP3 was an uncoupling pro-
tein (32-34). The most convincing demonstration, 
however, of the uncoupling activity of UCP3 is the 
recent finding that UCP3 reconstituted into proteo-
liposomes in the presence of coenzyme Q and fat-
ty acids mediates a H+ transport that is fully sensi-
tive to purine nucleotides (35). The UCP3-induced 
uncoupling of oxidative phosphorylation observed 
in yeast models was recently re-evaluated and 
shown to be insensitive to the known activators or 
inhibitors of this protein, i.e. fatty acids or purine 
nucleotides, respectively (36). This suggests that 
the uncoupling observed in yeast mitochondria was 
an artifact. Good transfected cell models for the 
study of UCP3 putative uncoupling activity are 
therefore still lacking. 
It was observed that fasting, a condition under 
which energy sparing should have priority, induced 
a large increase in muscle UCP3 mRNA expression 
(37). This observation of the so-called "fasting para-
dox" raised important questions to the function of 
UCP3 and even suggested that it would not behave 
as an uncoupling protein in vivo. The controversy 
has now reached a point where an attempt to put 
together the various theories seems important. We 
will first present the hypotheses concerning the bi-
ological role of UCP3. Then, we will discuss the pos-
sibility that UCP3, if it is not thermoregulatory, 
would nevertheless be thermogenic in vivo. 
The hypothesis that UCP3 would be a thermogenic 
protein seemed to be supported by the observa-
tion that transgenic mice overexpressing UCP3 in 
their skeletal muscle, despite the fact that they were 
hyperphagic, weighed less than their wild type con-
trols. In the mitochondria isolated from these trans-
genic mice decreased membrane potential and res-
piratory control and an increased state 4 respira-
tion compared to wild type mice mitochondria were 
observed (38). However, this uncoupling of mito-
chondrial oxidative phosphorylation was recently 
shown not to be inhibited by guanosine diphos-
phate (GDP), suggesting that it was an artifact of 
transgenic expression (39). 
It is weil established that a low rate of electron flow 
in the respiratory chain associated with a high pro-
ton gradient ac ross the mitochondria membrane, 
like in state 4 respiration, increases mitochondria 
reactive oxygen species (ROS) production (40). 
Therefore, it was postulated that the UCP3 function 
would be, by mildly uncoupling oxidative phos-
phorylation, to limit ROS production. This hypoth-
esis was supported by the observation that UCP3 
knockout mouse muscle mitochondria produced 
more ROS than wild type mitochondria (41). Re-
cently, it was shown in isolated rat skeletal muscle 
mitochondria that proton conductance was in-
creased by superoxides and that this increase was 
fatty acid-dependent and inhibited by GDP (42). An 
extension of this observation in vivo, would mean 
that the price to pay for avoiding ROS accumula-
tion is a stimulation of UCP3 activity and a decrease 
in the efficiency of aerobic ATP production. 
The "fasting paradox" and the observation that an 
increase in fatty acids disposal up-regulates muscle 
UCP3 expression (32-34) suggested 2 further hy-
potheses. The first is that the UCP3 role would be 
to prevent fatty acid accumulation in the mito-
chondria matrix by mediating the outward translo-
cation of fatty acids (43). This implies that UCP3, 
functioning as a fatty acid anion carrier, is an un-
coupling protein. The second hypothesis postu-
lates that UCP3 participates directly in fatty acid 
degradation and may be a member of the ß-oxi-
dation pathway (44, 33, 34). It implies that UCP3 
might paradoxically contribute to a net production 
of A TP. Th is latter theory is su pported by recent 
observations of the regulatory effect of AMP kinase 
(AMPK) on UCP3. The activation of AMPK is a key 
event in the stimulation of fatty acid degradation 
and of glucose uptake by muscle contraction (45). 
It would function as a "fuel gauge" signaling an 
ATP deficit. Recently, skeletal muscle AMPK acti-
vation by physical exercise or by its specific acti-
vator 5' -amino-4-imidazolecarboxamide ribonu-
cleoside (AICAR) was found to increase UCP3 ex-
pression (46). 
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Human skeletal muscle is a heterogeneous tissue 
comprising of type I (slow oxidative), type Ila (fast 
oxidative glycolytic) and type Ilx (fast-glycolytic) 
muscle fibers. Type 11 have a lower oxidative effi-
ciency than type I muscle fibers, with the P:O ratio 
found to be 18% lower in the former (47,48). It has 
been observed that UCP3 protein content is ex-
pressed decrescendo in Ilx>lla>1 muscle fiber types 
in both healthy and diabetic subjects (49) as weil as 
in endurance trained cyclists. The higher UCP3 pro-
tein content in type 11 than in type I fibers might, in 
part, be responsible for their observed lower phos-
phate oxygen (P:O) ratio of type II fibers. 
In humans, UCP3 mRNA (50,51) and protein levels 
(43) have been shown to be lower in endurance 
trained cyclists as compared to healthy control sub-
jects. Additionally, we have recently observed that 
the UCP3 protein content is lower in all fiber types 
of endurance trained when compared to healthy in-
dividuals. The interpretation of these results, wh ich 
imply the belief that UCP3 is an uncoupling pro-
tein, would be that the increase in the efficiency of 
muscle oxidative metabolism observed after en-
durance training should be partly a result of re-
duced UCP3 expression. 
Patients suffering from chronic obstructive pulmonary 
disease (COPD) demonstrate an impairment in their 
muscle oxidative metabolism, muscle weakness and 
exercise intolerance (52). A decrease in the oxida-
tive enzyme activities of citrate synthase and 3-hy-
droxyacyl coenzyme Adehydrogenase and an in-
crease in cytochrome c oxidase activity have also 
been observed (53). COPD patients also dem on-
strate a reduction in the cross sectional area of type 
I and type Ila muscle fibers indicating muscle atro-
phy (53). We have recently found that UCP3 mRNA 
expression is lower in muscle biopsies from COPD 
patients when compared to healthy age-matched 
controls. The lower UCP3 mRNA level in COPD pa-
tients may be a protective response to limit any fur-
ther impairment in their oxidative capacity and mus-
cle atrophy. 
Human UCP3 genetic studies might help to elucidate 
the biological role ofthis protein in vivo. Such studies 
so far have shown only weak associations between 
some of the UCP3 variants and obesity traits. Re-
cently, a new GA repeat microsatellite located in 
UCP3 gene intervening sequence 6 (GAIVS6) was an-
alyzed in the Quebec family. Strong associations were 
observed between some alleles and the BMI and the 
percent body fat (54). Suggestive linkages were also 
found in the Heritage family between GAIVS6 and 
changes in fat mass and percent body fat after en-
durance training (55). These results showing associa-
tions between UCP3 and obesity or body composi-
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tion changes after exercise suggest a role for this pro-
tein in energy expenditure. 
The question of the biological role of UCP3 is con-
troversial. Four hypotheses which are not neces-
sarily exclusive of each other are presently prevail-
ing. Our data in human museie and genetic stud-
ies support the idea that UCP3 is an uncoupling 
protein involved in energy expenditure. UCP3 exact 
function, however, remains to be defined. Mean-
while, UCP3 might still be a good candidate as a 
target far anti-obesity drugs. 
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